Medical treatment of senile cataract: clinical investigation of bendazac-lysine using objective and subjective methods.
A modified Zeiss slit lamp coupled with a digital image-processing system was used to evaluate objectively changes in lens transparency over 1 year at 4-month intervals in 150 eyes of 92 patients affected by early senile cataract. A total of 59 patients were treated daily with 1.5 g bendazac-lysine, and 33 patients constituted the control group. At follow-up, visual acuity was also tested using Snellen letter charts at variable contrast to provide an additional parameter closer to traditional methods. Results indicate that the minimal angle of resolution at 10% contrast (MAR10) and the mean gray-level value of the lens image obtained by retroillumination (MLR) are sensitive to early changes in lens transparency. Using MAR10 as a parameter, the control group showed a significant, progressive worsening of the lens status over 12 months, whereas the treated group exhibited no significant changes. MRL indicated the same behaviour as MAR10, although lens damage was detected later in the control group. The results show that bendazac-lysine may delay the formation of lens opacities.
Baraldi
P
P
Laboratorio di Bioingegneria, Università di Modena, Italy.
Fonda
S
S
Toschi
P
P
Benassi
B
B
Luppi
M L
ML
Penne
A
A
Mazza
C
C
Bocca
E
E
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging; D002386:Cataract / Q000188:drug therapy*; D015350:Contrast Sensitivity; D003720:Densitometry; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007191:Indazoles / Q000627:therapeutic use*; D007368:Interferometry; D007908:Lens, Crystalline / Q000187:drug effects / Q000473:pathology; D008027:Light; D008297:Male; D008875:Middle Aged; D011720:Pyrazoles / Q000627:therapeutic use*; D014792:Visual Acuity
D007191:Indazoles; D011720:Pyrazoles; C036067:bendazac lysine